blinatumomab (Blincyto®)

Reference No. 589

Publication date:

27/07/2016

Appraisal information

blinatumomab (Blincyto®) 38.5 microgram/vial powder for concentrate and solution for solution for infusion

Company:	Amgen Ltd
BNF category:	Malignant disease and immunosupression
NMG meeting date:	08/06/2016
AWMSG meeting date:	13/07/2016

Submission Type:	Full Submission
Status:	Superseded
Advice No:	1916
Ratification by Welsh Government:	26/07/2016

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA450) NICE GUIDANCE ISSUED JUNE 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation (FAR)

Download

blinatumomab (Blincyto) 589 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

blinatumomab (Blincyto) 589 ASAR

Clinical Expert (CE) Summary

Download

blinatumomab (Blincyto) 589 CE summary